Payment overview · 2025
General Payments
$2,660.94
117 reported records · 28 companies
Healthcare provider profile · identity verified
Lori Schaffer, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DU BOIS, PA · NPI 1184167090
Verified facts
What the public records show
CMS Open Payments records show Lori Schaffer, CRNP received $2,660.94 in general payments during 2025 across 117 reported records.
Novo Nordisk Inc accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Nurtec Odt, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $402.57 | 15.1% | 20 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $352.76 | 13.3% | 15 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $241.02 | 9.1% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $222.61 | 8.4% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $204.99 | 7.7% | 10 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $187.18 | 7.0% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $98.01 | 3.7% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $97.66 | 3.7% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $97.10 | 3.6% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $83.36 | 3.1% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $69.11 | 2.6% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $66.01 | 2.5% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $59.12 | 2.2% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $56.15 | 2.1% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $49.91 | 1.9% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $49.29 | 1.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.31 | 1.7% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $44.30 | 1.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.75 | 1.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $33.79 | 1.3% | 2 | 2025 |
| QIAGEN, LLC | Unresolved — no canonical attribution shown | $27.69 | 1.0% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $27.23 | 1.0% | 1 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $22.74 | 0.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.08 | 0.8% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.96 | 0.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.49 | 0.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.60 | 0.6% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $12.15 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,660.94 | 117 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $241.02 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $222.61 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $215.30 | 12 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $187.27 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $174.10 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $163.87 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $156.78 | 8 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $149.00 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $148.29 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $106.11 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $98.01 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $97.10 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $87.14 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $83.36 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $70.08 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $69.11 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $66.01 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $63.78 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $56.15 | 3 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $53.83 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $49.91 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.31 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.31 | 3 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $44.30 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $44.30 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $39.75 | 2 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $38.18 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.57 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $33.79 | 2 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $27.23 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $26.13 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $22.08 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $12.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 213 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 50 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 148 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | 16 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
213 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | 20 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
148 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
213 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 595 | 114 |
| Gabapentin | Gabapentin | 565 | 106 |
| Lisinopril | Lisinopril | 492 | 125 |
| Atorvastatin Calcium | Atorvastatin Calcium | 480 | 121 |
| Oxycodone Hcl | Oxycodone Hcl | 395 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 377 | 79 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 338 | 70 |
| Simvastatin | Simvastatin | 334 | 82 |
| Losartan Potassium | Losartan Potassium | 305 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 278 | 63 |
| Montelukast Sodium | Montelukast Sodium | 267 | 50 |
| Potassium Chloride | Potassium Chloride | 258 | 53 |
| Metformin Hcl | Metformin Hcl | 243 | 63 |
| Tramadol Hcl | Tramadol Hcl | 229 | 71 |
| Omeprazole | Omeprazole | 228 | 55 |
| Eliquis | Apixaban | 213 | 33 |
| Trazodone Hcl | Trazodone Hcl | 211 | 41 |
| Lorazepam | Lorazepam | 210 | 48 |
| Furosemide | Furosemide | 198 | 45 |
| Famotidine | Famotidine | 188 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 181 | 55 |
| Celecoxib | Celecoxib | 175 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 170 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 160 | 33 |
| Sertraline Hcl | Sertraline Hcl | 156 | 36 |
| Ozempic | Semaglutide | 148 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 135 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 126 | 20 |
| Alprazolam | Alprazolam | 125 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 123 | 17 |
| Prednisone | Prednisone | 117 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 117 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 25 |
| Pregabalin | Pregabalin | 105 | 21 |
| Carvedilol | Carvedilol | 104 | 28 |
| Baclofen | Baclofen | 101 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 98 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 95 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 26 |
| Meloxicam | Meloxicam | 92 | 21 |
| Alendronate Sodium | Alendronate Sodium | 90 | 15 |
| Mirtazapine | Mirtazapine | 87 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 86 | 25 |
| Fenofibrate | Fenofibrate Nanocrystallized | 83 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 27 |
| Allopurinol | Allopurinol | 79 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 75 | 62 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 74 | 23 |
| Jardiance | Empagliflozin | 72 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 71 | 12 |
| Levetiracetam | Levetiracetam | 69 | 12 |
| Nystatin | Nystatin | 68 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 67 | 23 |
| Clonazepam | Clonazepam | 66 | 17 |
| Morphine Sulfate Er | Morphine Sulfate | 66 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 66 | suppressed |
| Xarelto | Rivaroxaban | 66 | 12 |
| Morphine Sulfate | Morphine Sulfate | 65 | 20 |
| Ondansetron Odt | Ondansetron | 65 | 13 |
| Lansoprazole | Lansoprazole | 64 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 51 |
| Buspirone Hcl | Buspirone Hcl | 63 | 14 |
| Propranolol Hcl | Propranolol Hcl | 63 | 11 |
| Fentanyl | Fentanyl | 59 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 59 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 16 |
| Methocarbamol | Methocarbamol | 55 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 13 |
| Bumetanide | Bumetanide | 54 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 11 |
| Fluconazole | Fluconazole | 54 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 20 |
| Ezetimibe | Ezetimibe | 52 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 50 | 16 |
| Bupropion Xl | Bupropion Hcl | 49 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Spironolactone | Spironolactone | 42 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | suppressed |
| Glipizide Er | Glipizide | 40 | suppressed |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 11 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Xtampza Er | Oxycodone Myristate | 39 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 19 |
| Sucralfate | Sucralfate | 38 | 13 |
| Diazepam | Diazepam | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | suppressed |
| Ibuprofen | Ibuprofen | 34 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Lactulose | Lactulose | 30 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 30 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Calcitriol | Calcitriol | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Metolazone | Metolazone | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 17 |
| Topiramate | Topiramate | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | 14 |
| Etodolac | Etodolac | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 18 |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 15 |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 12 |
| Finasteride | Finasteride | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Metaxalone | Metaxalone | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Contrave | Naltrexone Hcl/Bupropion Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Topamax | Topiramate | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,660.94 · 117 records | Novo Nordisk Inc | AIRSUPRA, AMVUTTRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, DAYBUE, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, FANAPT, FARXIGA, FREESTYLE LIBRE 3, HETLIOZ, IBSRELA, INSPIRE, KEVEYIS, LEQVIO, LifeVest, NUPLAZID, NURTEC ODT, ONPATTRO, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SX-ONE MICROKNIFE, TRELEGY ELLIPTA, TWIIST, UBRELVY, VOQUEZNA, VYNDAMAX, VYNDAQEL, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error